Class Action Lawsuit Filed On Behalf Of Investors Of Immunovant, Inc., f/k/a Health Sciences Acquisitions Corporation, – IMVT Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
On February 19, 2021, a class action lawsuit was filed on behalf of investors of Immunovant, Inc., f/k/a Health Sciences Acquisitions Corporation, (“Immunovant” or the “Company”) (NASDAQ: IMVT) who purchased, or otherwise acquired IMVT securities between October 2, 2019 and February 1, 2021, both dates inclusive (the “Class Period).
According to the class action complaint, throughout the Class Period, the Immunovant Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.
The Immunovant Defendants, according to the class action complaint, made false and/or misleading statements and/or failed to disclose that: (i) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (ii) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (iii) the foregoing foreseeably diminished IMVT-1401’s prospects for regulatory approval, commercial viability, and profitability; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, IMMUNOVANT SECURITIES DURING THE CLASS PERIOD AND SUFFERED LOSSES GREATER THAN $100,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT KEVIN CAULEY, DIRECTOR, BUSINESS DEVELOPMENT, (215) 792-6676, EXT. 802, [email protected], [email protected], [email protected], TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION OR POTENTIAL LEGAL CLAIMS.